The myelodysplastic syndromes and myeloproliferative disorders.
Our understanding of the exact molecular and genetic alterations responsible for the evolution of the diverse diseases included under the myelodysplastic and myeloproliferative disorders lags behind that of the acute leukemias and CML. However, progress is being made, and new tests for molecular markers (increased PRV-1/CD177, decreased Mpl expression) are being developed. While in the past, treatment for both groups of diseases was primarily supportive, an improved understanding of the underlying pathobiology has led to new treatments with promising preliminary results. The laboratory's role in the diagnosis, prognosis, and determination of efficacy of treatment will continue to expand as new tests become available.
Williams
J Lynne
JL
Medical Laboratory Sciences Program at Oakland University, Rochester, MI 48309-4482, USA. jlwillia@oakland.edu
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000503:physiopathology / Q000628:therapy*; D009196:Myeloproliferative Disorders / Q000145:classification* / Q000503:physiopathology / Q000628:therapy*; D011087:Polycythemia Vera / Q000628:therapy; D055728:Primary Myelofibrosis / Q000503:physiopathology / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000628:therapy
D000970:Antineoplastic Agents